← Back to Screener
Alpha Teknova, Inc. Common Stock (TKNO)
Price$2.91
Favorite Metrics
Price vs S&P 500 (26W)-49.67%
Price vs S&P 500 (4W)-4.48%
Market Capitalization$157.01M
All Metrics
Book Value / Share (Quarterly)$1.28
P/TBV (Annual)3.58x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.73%
Cash Flow / Share (Quarterly)$-0.18
Price vs S&P 500 (YTD)-27.03%
Gross Margin (TTM)33.17%
Net Profit Margin (TTM)-42.59%
EPS (TTM)$-0.32
10-Day Avg Trading Volume0.15M
EPS Excl Extra (TTM)$-0.32
Revenue Growth (5Y)5.30%
EPS (Annual)$-0.32
ROI (Annual)-21.07%
Gross Margin (Annual)33.17%
Net Profit Margin (5Y Avg)-70.98%
Cash / Share (Quarterly)$0.40
Revenue Growth QoQ (YoY)7.76%
ROA (Last FY)-16.66%
Revenue Growth TTM (YoY)7.35%
EBITD / Share (TTM)$-0.29
ROE (5Y Avg)-30.55%
Operating Margin (TTM)-41.90%
Cash Flow / Share (Annual)$-0.18
P/B Ratio2.28x
P/B Ratio (Quarterly)2.96x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)4.05x
Net Interest Coverage (TTM)-23.23x
ROA (TTM)-15.85%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)4.58x
Quick Ratio (Quarterly)3.44x
3-Month Avg Trading Volume0.21M
52-Week Price Return-49.22%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.06
P/S Ratio (Annual)3.87x
Asset Turnover (Annual)0.39x
52-Week High$7.48
Operating Margin (5Y Avg)-72.56%
EPS Excl Extra (Annual)$-0.32
CapEx CAGR (5Y)-26.82%
26-Week Price Return-40.93%
Quick Ratio (Annual)3.44x
13-Week Price Return-24.29%
Total Debt / Equity (Annual)0.19x
Current Ratio (Quarterly)4.58x
Enterprise Value$164.223
Revenue / Share Growth (5Y)-8.08%
Asset Turnover (TTM)0.37x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.91x
Pretax Margin (Annual)-42.45%
Cash / Share (Annual)$0.40
3-Month Return Std Dev91.13%
Gross Margin (5Y Avg)34.07%
Net Income / Employee (TTM)$-0
ROE (Last FY)-25.09%
Net Interest Coverage (Annual)-23.23x
EPS Basic Excl Extra (Annual)$-0.32
Receivables Turnover (TTM)9.07x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$-0.32
Receivables Turnover (Annual)9.07x
ROI (TTM)-19.82%
P/S Ratio (TTM)3.87x
Pretax Margin (5Y Avg)-73.62%
Revenue / Share (Annual)$0.76
Tangible BV / Share (Annual)$1.06
Price vs S&P 500 (52W)-84.31%
Year-to-Date Return-22.89%
5-Day Price Return-2.98%
EPS Normalized (Annual)$-0.32
ROA (5Y Avg)-20.97%
Net Profit Margin (Annual)-42.59%
Month-to-Date Return1.38%
Cash Flow / Share (TTM)$-1.21
EBITD / Share (Annual)$-0.29
Operating Margin (Annual)-41.90%
LT Debt / Equity (Annual)0.19x
ROI (5Y Avg)-25.97%
LT Debt / Equity (Quarterly)0.19x
EPS Basic Excl Extra (TTM)$-0.32
P/TBV (Quarterly)3.58x
P/B Ratio (Annual)2.96x
Inventory Turnover (TTM)3.91x
Pretax Margin (TTM)-42.45%
Book Value / Share (Annual)$1.28
Price vs S&P 500 (13W)-27.15%
Beta0.30x
Revenue / Share (TTM)$0.76
ROE (TTM)-23.32%
52-Week Low$1.91
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.08
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TKNOAlpha Teknova, Inc. Common Stock | 3.87x | 7.35% | 33.17% | — | $2.91 |
IDXXIdexx Laboratories Inc | 10.72x | 10.42% | 61.80% | 14.28% | $583.06 |
LNTHLantheus Holdings, Inc | 3.55x | 0.50% | 61.10% | 40.71% | $83.97 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 295.25x | -5.72% | 89.00% | — | $26.98 |
CLDXCelldex Therapeutics, Inc | 1753.49x | -77.98% | 17.65% | — | $34.38 |
NEOGNeogen Corp | 2.39x | -3.91% | 45.20% | — | $9.63 |
NTLAIntellia Therapeutics, Inc | 26.55x | 16.92% | — | — | $15.21 |
QDELQuidelOrtho Corporation Common Stock | 0.32x | -1.89% | 46.67% | — | $12.89 |
MYGNMyriad Genetics Inc | 0.59x | -1.56% | 69.93% | — | $5.14 |
ACHVAchieve Life Sciences, Inc. | 12.70x | -89.25% | — | — | $4.25 |
IMDXInsight Molecular Diagnostics Inc. Common Stock | 31.65x | 115.58% | 56.97% | — | $3.99 |
About
Alpha Teknova Inc manufactures critical reagents used in the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company offers two primary product lines—Lab Essentials and Clinical Solutions—comprised of pre-poured culture media plates, liquid microbial media, and molecular biology reagents for sample preparation and purification. Primary revenue is generated from the United States market.